PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30482615-0 2019 Sodium butyrate inhibits the production of HMGB1 and attenuates severe burn plus delayed resuscitation-induced intestine injury via the p38 signaling pathway. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 43-48 30482615-2 2019 Sodium butyrate, a histone deacetylase inhibitor, has potential anti-inflammatory properties, inhibiting the expression of inflammatory mediators such as HMGB1 in diverse diseases. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 154-159 30482615-10 2019 Sodium butyrate administration significantly inhibited the HMGB1 expression in the intestine, decreased the DAO concentration in plasma, reduced the intestinal I-FABP expression, and improved the intestinal histologic changes induced by burn injury plus delayed resuscitation. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 59-64 30482615-12 2019 CONCLUSIONS: Sodium butyrate inhibits HMGB1 expression which could be attributed to p38 MAPK signal transduction pathway and decreases intestinal inflammatory responses and oxidative stress, thus attenuates burn plus delayed resuscitation-induced intestine injury. Butyric Acid 13-28 high mobility group box 1 Rattus norvegicus 38-43 30465396-9 2018 Compared with the 18 h crush group, the expression levels of the ERS-related proteins and HMGB1 protein in rat lung tissues were attenuated in 18 h crush+SB group, and the pathological changes of rat lung injury began to alleviate. Butyric Acid 154-156 high mobility group box 1 Rattus norvegicus 90-95 24919615-13 2014 Compared to the model group, sodium butyrate treatment significantly improved the histopathological changes in the liver and intestine, reduced serum endotoxin and inflammatory cytokines, suppressed HMGB1 and NF-kappaB p65 proteins in liver tissue, and prolonged the survival duration regardless of treatment at 12 hours or 24 hours after induction of ALF (P<0.05). Butyric Acid 29-44 high mobility group box 1 Rattus norvegicus 199-204 24944626-2 2014 Sodium butyrate, an inhibitor of histone deacetylase, has been shown to inhibit HMGB1 expression. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 80-85 24944626-9 2014 Furthermore, treatment with sodium butyrate (300 mg/kg) was found to significantly inhibit the expression of TNF-alpha, IL-6 and HMGB1 induced by I/R injury (P<0.05). Butyric Acid 28-43 high mobility group box 1 Rattus norvegicus 129-134 29663989-5 2018 The experiment 2 was divided into control group, crush model group (18 hours after crush), HMGB1 inhibitor sodium butyrate (SB) or ethyl pyruvate (EP) groups, and SB or EP treatment groups (500 mg/kg SB solution or 40 mg/kg EP solution was injected intraperitoneally after 3 hours crush). Butyric Acid 107-122 high mobility group box 1 Rattus norvegicus 91-96 23874764-3 2013 Sodium butyrate, an inhibitor of histone deacetylase, has been demonstrated to inhibit HMGB1 expression. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 87-92 23874764-10 2013 As a result, sodium butyrate significantly inhibited the HMGB1 expressions in the lungs, reduced the lung W/D ratio, and improved the pulmonary histologic changes induced by burn trauma. Butyric Acid 13-28 high mobility group box 1 Rattus norvegicus 57-62 23874764-12 2013 These results suggest that sodium butyrate attenuates inflammatory responses, neutrophil infiltration, and oxidative stress in the lungs, and protects against remote ALI induced by severe burn, which is associated with inhibiting HMGB1 expression. Butyric Acid 27-42 high mobility group box 1 Rattus norvegicus 230-235 17505308-1 2007 This study was performed to investigate a novel strategy to pharmacologically inhibit high-mobility group box 1 protein (HMGB1) expression with sodium butyrate, a short-chain fatty acid. Butyric Acid 144-159 high mobility group box 1 Rattus norvegicus 86-111 17505308-1 2007 This study was performed to investigate a novel strategy to pharmacologically inhibit high-mobility group box 1 protein (HMGB1) expression with sodium butyrate, a short-chain fatty acid. Butyric Acid 144-159 high mobility group box 1 Rattus norvegicus 121-126 17505308-7 2007 Sodium butyrate can markedly inhibit HMGB1 mRNA expression and may have protective effect on multiple organ damage in sepsis. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 37-42 18952078-1 2008 OBJECTIVE: To observe the effects of intravenous injection of HMGB1 inhibitor sodium butyrate on changes in apoptosis of PMN during LPS-induced acute lung injury in rats and HMGB1 in vitro on human circulating PMN apoptosis, in order to clarify the role of HMGB1 in the pathogenesis of acute lung injury. Butyric Acid 78-93 high mobility group box 1 Rattus norvegicus 62-67 18952078-20 2008 Sodium butyrate (SB) treatment attenuated LPS-induced PMN apoptosis delay and inhibition, and down-regulated HMGB1 mRNA expression of injured lung. Butyric Acid 0-15 high mobility group box 1 Rattus norvegicus 109-114 18952078-20 2008 Sodium butyrate (SB) treatment attenuated LPS-induced PMN apoptosis delay and inhibition, and down-regulated HMGB1 mRNA expression of injured lung. Butyric Acid 17-19 high mobility group box 1 Rattus norvegicus 109-114 12882679-5 2003 RESULTS: HMG-1 mRNA levels significantly increased in various tissues during 6 - 72 h after CLP (P < 0.05 or 0.01), and were markedly inhibited by sodium butyrate at 12 h and 24 h (P < 0.05 or 0.01). Butyric Acid 150-165 high mobility group box 1 Rattus norvegicus 9-14